Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Daniel J. Haraf, MD, professor of Radiation & Cellular Oncology, medical Director, Radiation Oncology, The University of Chicago Medicine, discusses a more focused approach to radiation therapy in head and neck cancer. Haraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Haraf said a recent study shows that an approach of induction chemotherapy utilized in 100 patients, without any elective nodal radiation, resulted in a positive response for 99 of the 100 patients. Haraf said these results are "practice changing" and could result in confined radiotherapy with less toxicities.
FDA Grants Fast Track Designation to MVR-T3011 in HNSCC
March 20th 2024The FDA fast-tracked MVR-T3011, an intratumorally injected oncolytic virus, for treating recurrent or metastatic head and neck squamous cell cancer post-platinum chemotherapy and at least 1 prior anti-PD1/PDL1 therapy.
Read More
Behind the FDA Approval of Liso-cel for Relapsed/Refractory CLL/SLL
March 15th 2024In an interview with Targeted Oncology, Tanya Siddiqi, MD, discussed the rationale behind the TRANSCEND CLL 004 study supporting the FDA approval of lisocabtagene maraleucel in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More